The first patient population is HoFH, a rare genetic disorder afflicting approximately 1 in 250,000 individuals characterized by severe hepatic LDLR-deficiency leading to impaired removal of LDL-C from the circulation and LDL-C concentrations several times normal, and markedly accelerated atherosclerosis13. This evidence concerns the gene LDLR and hereditary disease.